Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03316456 · ClinicalTrials.gov registry record
Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- 20
- Enrollment target
NCT03316456 is a clinical trial that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 20 participants.
The verdict
NCT03316456 has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is an observational study to collect stool, blood, and urine from acute leukemia patients undergoing induction chemotherapy in order to generate preliminary data regarding the association between microbiota and chemotherapy-induced gut barrier damage. This study consists of inpatient collections of blood, urine, and stool while the patients are undergoing inpatient induction therapy. Patients will not be scheduled for any additional procedures or testing beyond what is required for clinical care.
Interventions
- DIAGNOSTIC_TEST Observational: Stool Sample Collection
- DIAGNOSTIC_TEST Observational: Blood Sample Collection
- DIAGNOSTIC_TEST Observational: Urine Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-08-22 |
| Est. Completion | 2019-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03316456
The ClinicalTrials.gov registry entry for NCT03316456 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Observational: Stool Sample Collection is the first listed.
NCT03316456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03316456 about?
NCT03316456 is a clinical study titled "Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction". This is an observational study to collect stool, blood, and urine from acute leukemia patients undergoing induction chemotherapy in order to generate preliminary data regarding the association between microbiota and chemotherapy-induced gut barrier damage. This study consists of inpatient collection...
What is the current status of trial NCT03316456?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-08-22. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03316456?
The interventions under investigation include: Observational: Stool Sample Collection (DIAGNOSTIC_TEST), Observational: Blood Sample Collection (DIAGNOSTIC_TEST), Observational: Urine Sample Collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03316456?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.